Biotech Values

[DewDiligence]

ENTA—The facts: • Goldberg and Poorvin resignation indicates that a major conflict is taking place on the ENTA BoD.

I don’t think it’s a foregone conclusion that there is a major conflict on the existing BoD. If there were, the statement in ENTA’s 8-K that the resignations are “not the result of any disagreement with Enanta on any matter relating to its operations, policies or practices” would be untrue and might be legally actionable.

An alternative explanation (the one mentioned in #msg-95809197) is that the impetus for the resignations is to shrink the board size to give more power to each director, especially Luly.

It is expected that, following a completion of HCV registration trials with ABBV, ENTA will be sold (unless the expected results are a complete failure).

Expected by whom?